163 related articles for article (PubMed ID: 14971882)
1. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment.
Jumper C; Cobos E; Lox C
Respir Med; 2004 Feb; 98(2):173-7. PubMed ID: 14971882
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
5. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
6. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy.
Susskind H; Hymowitz MH; Lau YH; Atkins HL; Hurewitz AN; Valentine ES; Meek AG; Zucker S
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1161-9. PubMed ID: 12829155
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer.
An HJ; Lee YJ; Hong SA; Kim JO; Lee KY; Kim YK; Park JK; Kang JH
Pathol Res Pract; 2016 May; 212(5):357-64. PubMed ID: 26995105
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis.
El-Badrawy MK; Yousef AM; Shaalan D; Elsamanoudy AZ
J Bronchology Interv Pulmonol; 2014 Oct; 21(4):327-34. PubMed ID: 25321452
[TBL] [Abstract][Full Text] [Related]
10. [Effect of cisplatin on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their correlations in Lewis lung cancer in mice].
Li CJ; Sun JL; Jiang WJ; Liu LS; Sun XY; Fan GZ
Ai Zheng; 2009 Jul; 28(7):685-90. PubMed ID: 19624892
[TBL] [Abstract][Full Text] [Related]
11. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.
Michael M; Babic B; Khokha R; Tsao M; Ho J; Pintilie M; Leco K; Chamberlain D; Shepherd FA
J Clin Oncol; 1999 Jun; 17(6):1802-8. PubMed ID: 10561218
[TBL] [Abstract][Full Text] [Related]
13. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
14. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells.
González-Avila G; Iturria C; Vadillo F; Terán L; Selman M; Pérez-Tamayo R
Pathobiology; 1998; 66(1):5-16. PubMed ID: 9577961
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
17. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Reckamp KL; Gardner BK; Figlin RA; Elashoff D; Krysan K; Dohadwala M; Mao J; Sharma S; Inge L; Rajasekaran A; Dubinett SM
J Thorac Oncol; 2008 Feb; 3(2):117-24. PubMed ID: 18303430
[TBL] [Abstract][Full Text] [Related]
18. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
19. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer.
Safranek J; Holubec L; Topolcan O; Pesta M; Klecka J; Vodicka J; Finek J; Kormunda S; Pesek M
Anticancer Res; 2007; 27(4C):2953-6. PubMed ID: 17695477
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
